Table 1 Summary of engraftment rates of PDX tumors
From: Patient-derived xenografts as compatible models for precision oncology
Tumor type | Mice strain | Implantation site | Engraftment rate | Engraftment-related factors | References |
|---|---|---|---|---|---|
Colorectal cancer | NSG | Subcutaneous | 76% | Â | Cho et al., 2019 [11] |
| Â | Nude | Orthotopic | 89% | Â | Aytes et al., 2012 [12] |
Pancreatic cancer (ductal adenocarcinoma) | Nude | Subcutaneous | 45% | Post-operation CA 19–9 level | Chen et al., 2020 [13] |
| Â | ICR SCID | Subcutaneous | 67% | Â | Mattie et al., 2013 [14] |
Breast cancer | SCID/Beige, NSG | Mammary fat pad | 19–21% |  | Zhang et al., 2013 [20] |
| Â | NOD/SCID | Humanized mammary fat pad | 13% | Â | Li et al., 2013 [21] |
Non-small cell lung cancer | Nude, NOG | Subcutaneous | 41% | Brain metastasis, SCC histology, tumor stage, wild-type EGFR | Lee et al., 2015 [15] |
| Â | NOD/SCID | Renal capsule | 90% | Â | Dong et al., 2010 [16] |
Gastric cancer | NOG | Subcutaneous | 24% | Intestinal type, high tumor cell percentage, short procedure time | Choi et al., 2016 [22] |
Liver cancer (hepatocellular carcinoma) | NSG | Subcutaneous, orthotopic | 14% | Â | Zhu et al., 2020 [23] |
Kidney cancer (renal cell carcinoma) | NOD/SCID | Orthotopic (Renal capsule) | 37% | Tumor stage, Tumor implanted from metastatic site | Sivanand et al., 2012 [24] |
Bladder cancer (urothelial carcinoma) | BALB/ c-nu | Subcutaneous | 15% | Â | Park et al., 2013 [25] |
Biliary tract cancer (cholangiocarcinoma and gallbladder cancers) | NOD/SCID | Subcutaneous | 54% | Surgical resection, median ischemic time | Leiting, 2020 [17] |
Head and neck cancer (squamous cell carcinoma) | NSG | Subcutaneous | 85% | Lymph node positive | Kimple et al., 2013 [18] |
Medulloblastoma | Rag2 SCID | Orthotopic | 52% | Â | Zhao et al., 2012 [19] |
Uveal melanoma | NOD/SCID | Subcutaneous | 28% | Metastasis | Némati et al., 2010 [26] |